CGMP Latanoprostene Bunod
![CGMP Latanoprostene Bunod](/46/product/129/00/48/37850.png)
Product Description
Cayman Pharma s.r.o
![Cayman Pharma s.r.o](/cayman_pharma_hex_300x300-comp244892.png)
-
CZ
-
2015On CPHI since
-
3Certificates
-
100 - 249Employees
Company types
Primary activities
Categories
Specifications
Cayman Pharma s.r.o
![Cayman Pharma s.r.o](/cayman_pharma_hex_300x300-comp244892.png)
-
CZ
-
2015On CPHI since
-
3Certificates
-
100 - 249Employees
Company types
Primary activities
More Products from Cayman Pharma s.r.o (4)
-
Product CGMP Bimatoprost
Bimatoprost is a potent FP receptor agonist that finds clinical use as an ocular hypotensive agent for the treatment of glaucoma. The DMF is on file with the US FDA, Brazil, Canada and India. -
Product CGMP Epoprostenol sodium salt
Epoprostenol is a potent vasodilator and antiplatelet substance with a very short physiological half-life. It is used for the treatment of pulmonary hypertension. The DMF for Epoprostenol Sodium Salt is on file with the US FDA, Canada, Japan, Australia, Switzerland and most EU member states. -
Product CGMP Cloprostenol sodium salt
Cloprostenol sodium salt is used in veterinary medicine as a luteolytic agent for the induction of estrus and the treatment of reproductive disorders in cattle, swine, and horses. Cloprostenol sodium salt is manufactured at Cayman Pharma both in racemic form (CAS No.: 55028-72-3) and optically active form ... -
Product CGMP Latanoprost
Latanoprost is the most widely used prostaglandin for the treatment of elevated intraocular pressure in glaucoma. Latanoprost is manufactured at Cayman Chemical (Ann Arbor, MI, USA) and at Cayman Pharma (Czech Republic). GMP material from both Cayman Chemical and Cayman Pharma, which conforms to the USP, E...
Cayman Pharma s.r.o resources (2)
-
News Cayman Chemical Receives CEP for Latanoprost API from EDQM
ANN ARBOR, MI, SEPTEMBER 12, 2023—Cayman Chemical, a world leader in the manufacture of prostaglandins for both research use and as active pharmaceutical ingredients (APIs), has been granted a Certification of Suitability to the monographs of the European Pharmacopoeia (CEP) by the European Directorate for the Quality of Medicines and HealthCare (EDQM) for its latanoprost API, effective August 28th, 2023. Cayman Chemical is the first company in the USA to receive a CEP for latanoprost. -
Brochure API Manufacturing
Learn more about the importance of process understanding and Cayman's commercial API production
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance